secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001104659-25-022763
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports FY2024 net loss of $45.6M; advances denifanstat Phase 3 in MASH and TVB-3567 IND clearance
--------------------------------------------------------------------------------

- Full year 2024 net loss $45.6M ($27.9M in 2023); R&D expense $38.4M, up from $19.8M.
- Cash $158.7M at Dec 31, 2024; funded by Jan 2024 follow-on offering of 9M shares netting $104.7M.
- Phase 3 denifanstat program for MASH initiated; patient screening expected 1H 2025; includes FASCINATE-3 and FASCINIT.
- FDA granted Breakthrough Therapy designation for denifanstat in non-cirrhotic MASH with F2/F3 fibrosis.
- IND cleared for TVB-3567, a second FASN inhibitor for acne; Phase 1 trial planned in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/0001104659-25-022763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-022763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer